Samina Hamied, third-generation heir to Cipla, challenges herself with marathons all over the world. She had joined the business after working for Goldman Sachs in U.S. and was expected to hit the ground running at 35 after Amar Lulla, MD for over 30 years, passed away in 2011. Cipla entered the U.S. market in 2015 under her leadership with strategic partnerships and acquisitions. The company reported a turnover of ₹21,763 crore in FY22 compared to ₹19,160 crore in FY21. Profit rose 4.7% to ₹2,517 crore from ₹2,405 crore in FY21.
“One area we are betting on is respiratory therapy with investments in biosimilars & peptides. Active exploration of m-RNA is fuelling our innovation engine with a robust range of offerings comprising innovative drug-device combinations and even bio-drugs,” says Hamied. She is also transforming Cipla into a digitally agile company. “We are creating plants of the future (with AI, Robotics, Augmented/Virtual Mixed Reality) that facilitate interconnected, touchless operations across our manufacturing and supply chain.” — Gina Krishnan